Profile
Roy S.
Walzer is currently the Director at Cell Analysis Ltd.
and also holds the position of President & Treasurer at Litchfield Equities Ltd.
In the past, he worked as a Director at Advanced Viral Research Corp.
from 2002 to 2009.
Roy S. Walzer active positions
Companies | Position | Start |
---|---|---|
Cell Analysis Ltd.
Cell Analysis Ltd. BiotechnologyHealth Technology Cell Analysis Ltd. develops applications and solutions based on cell analysis. It offers food authenticity, agricultural breed genetics, and diagnostic products for human genetic disorders. The company was founded in 1999 and is headquartered in Slough, the United Kingdom. | Director/Board Member | 2018-04-28 |
Litchfield Equities Ltd. | President | - |
Former positions of Roy S. Walzer
Companies | Position | End |
---|---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Director/Board Member | 2009-03-22 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
Cell Analysis Ltd.
Cell Analysis Ltd. BiotechnologyHealth Technology Cell Analysis Ltd. develops applications and solutions based on cell analysis. It offers food authenticity, agricultural breed genetics, and diagnostic products for human genetic disorders. The company was founded in 1999 and is headquartered in Slough, the United Kingdom. | Health Technology |
Litchfield Equities Ltd. |
- Stock Market
- Insiders
- Roy S. Walzer